Delaware SB120 requires health insurance policies to cover biomarker testing for diagnosis, treatment, and management of diseases.
Delaware SB120 amends the Delaware Code to mandate that all group and individual health insurance policies provide coverage for biomarker testing. This testing must be for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a covered person's disease or condition when supported by medical and scientific evidence. The bill specifies that coverage must be provided for biomarker testing when it aligns with labeled indications for FDA-approved or FDA-cleared tests, indicated tests for FDA-approved drugs, warnings and precautions on FDA-approved drug labels, and.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.